Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
NEWSLETTER  |  PRINT VERSION
Facebook
Twitter
LinkedIn
Cancer World Magazine
Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine > News > ESMO provides first recommendations on use of next-generation sequencing in metastatic cancer
  • News

ESMO provides first recommendations on use of next-generation sequencing in metastatic cancer

  • 8 September 2020
  • Janet Fricker
ESMO provides first recommendations on use of next-generation sequencing in metastatic cancer
Total
0
Shares
0
0
0
0
0
Patients with metastatic non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma should be offered next-generation sequencing (NGS) for profiling tumour samples, concludes an expert panel from the European Society for Medical Oncology (ESMO) in their review (Mosele F et al. Ann Oncol 2020) published in Annals of Oncology (August 24). “These are the first recommendations from a scientific society about the use of NGS,” said Dr Fernanda Mosele, the first author of the paper, from Gustave Roussy, Villejuif, France. “Our intent is that they will unify decision-making about how NGS should be used in patients with metastatic cancer.” NGS is a sequencing technology that assesses high numbers of nucleotides in a short time frame with the aim of selecting targeted treatments according to mutations detected. While it has been widely implemented, until now, no recommendations have been issued regarding use in daily practice. The ESMO Translational Research and Precision Medicine Working Group (Mateo J et al. Ann Oncol 2018) developed the new recommendations using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). This scale is a framework that ranks a match between drug and genomic alterations, according to actionability. For example, ESCAT level I means that the match of an alteration and drug has been validated in clinical trials; while ESCAT level III includes alterations validated in another cancer, but not in the disease-to-treat. For the current recommendations, all recurrent genomic alterations were identified in the eight cancers considered responsible for the most deaths worldwide. Then the ESCAT score was determined for each alteration. Finally, from the prevalence of alterations for each tumour type and the ESCAT ranking, the authors calculated the number of patients who would need to be tested with NGS to identify one patient who could be matched to an effective drug in daily practice. In the paper, ESMO makes recommendations at three different levels.
  • From the public health perspective, the authors recommend NGS should be used routinely in patients with metastatic lung adenocarcinoma, prostate cancer, ovarian cancer, and cholangiocarcinoma. In these tumours, large multigene panels could be used if they add acceptable extra cost compared with small panels. Additionally, based on the KN158 trial it is recommended to test tumour mutational burden (TMB) in well-and moderately-differentiated neuroendocrine tumours (NETs), cervical, salivary, thyroid and vulvar cancers, as TMB predicts response to the anti-PD-1 antibody pembrolizumab in these cancers.
  • From the clinical research perspective, centres should perform NGS to generate more evidence about use of this method and accelerate drug development.
  • From the patient-centric perspective, patients with other cancers can decide with their doctors to order NGS on a large panel of genes – providing there is no extra cost for the public healthcare system and the patient is informed about the relative likelihood of benefit.
The review found there to be no current indications for NGS in breast, squamous-cell lung, gastric, pancreatic, or hepatocellular carcinoma. However, the authors concluded that as new data emerge for novel therapies across tumour types the recommendations will need to be updated. Commenting on the publication, Ruth Plummer, Professor of Experimental Cancer Medicine at Newcastle University, UK, said, “These ESMO guidelines are an excellent distillation of the current data and provide clear recommendations for the tumour types where there is the best evidence NGS might be of benefit. They also provide a very comprehensive summary of the trial data available.” For routine clinical practice, she said, the guidelines will help physicians in discussions with patients about the benefits of having an NGS panel run on their tumour sample, and help guide NGS sequencing when resources are limited. In general, NGS sequencing for all patients with NSCLC, prostate cancers, ovarian cancers and cholangiocarcinoma, she added, was not currently available in all cancer centres across Europe. “Having clear European guidelines from ESMO will help inform discussions as health services move towards establishing routine NGS for cancer patients,” said Professor Plummer, who is deputy chair of the Cancer Drug Development Forum.
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • ESMO
  • guidelines
  • metastatic cancer
  • mutations
  • next generation sequencing
Avatar
Janet Fricker

Previous Article
  • Articles
  • Delivery of Care

Will artificial intelligence revolutionise cancer therapeutics and care?

  • 8 September 2020
  • Rachel Brazil
View Post
Next Article
  • News

New transatlantic partnership to regain the momentum of cancer research

  • 9 September 2020
  • Janet Fricker
View Post
You May Also Like
View Post
  • News

Study brings mass biparametric MRI screening for prostate cancer a step closer

  • Janet Fricker
  • 23 February 2021
View Post
  • News

Oncology providers urged to offer healthy life style advice to breast cancer survivors

  • Janet Fricker
  • 19 February 2021
View Post
  • News

Studies provide clarity on breast cancer genes for genetic panels

  • Janet Fricker
  • 9 February 2021
View Post
  • News

EC publishes route map for tackling cancer

  • Janet Fricker
  • 5 February 2021
View Post
  • News

Therapy targeting androgen receptors opens new chapter for hormone driven breast cancers

  • Janet Fricker
  • 27 January 2021
View Post
  • News

Coffee may protect against prostate cancer

  • Janet Fricker
  • 20 January 2021
View Post
  • News

Financial burden on older adults with advanced cancer worsens quality of life

  • Janet Fricker
  • 15 January 2021
View Post
  • News

Integrated imaging opens the way for virtual biopsies

  • Janet Fricker
  • 15 January 2021

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancer World archive
Latest news
  • Study brings mass biparametric MRI screening for prostate cancer a step closer
    • 23 February 2021
  • Oncology providers urged to offer healthy life style advice to breast cancer survivors
    • 19 February 2021
  • Studies provide clarity on breast cancer genes for genetic panels
    • 9 February 2021
  • EC publishes route map for tackling cancer
    • 5 February 2021
  • Therapy targeting androgen receptors opens new chapter for hormone driven breast cancers
    • 27 January 2021
Latest printed issue
Article
  • Natural killers: a new tactical unit joins the cancer immunotherapy brigade
    • 25 February 2021
  • Immunotherapy toxicities demand a joined up approach from oncologists and organ specialists
    • 24 February 2021
  • Beating cancer is complex – our messaging must be clear
    • 11 February 2021
Newsletter

Don't miss our newsletter

Would you like to receive our bimonthly e-newsletter with the latest news from Cancer World magazine?

Subscribe now
Social

Would you follow us ?

Contents
  • Moving towards efficiency in cancer care: Examples
    • 8 February 2021
  • World Cancer Day: we commemorate Professor Agim Sallaku
    • 3 February 2021
  • Gordon McVie 1945–2021: a lifetime dedicated to defeating cancer
    • 22 January 2021
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancer World is managed by SPCC Sharing Progress in Cancer Care | Piazza Indipendenza 2, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.